HIROAKI SERIZAWA

Company: AMD Therapeutics

Job title: CEO

Seminars:

Panel & Live Audience Discussion: Optimizing Drug Delivery to the Retina 10:00 am

Topical Solutions: Reviewing topical solutions as for retinal vascular diseases Gene Therapy: Overcoming existing hurdles surrounding the development of Ophthalmic gene therapies and their delivery Durable Formulations: Developing durable formulations for nAMD, DR and DME to achieve longer lasting deliveryRead more

day: Conference Day 2

Developing Durable Drug Formulations & Less Invasive Delivery Mechanisms to the Retina for Improved Patient Compliance 11:05 am

Many challenges arise when developing therapies for Wet AMD, DME, DR & RVO as therapeutics are aimed to be administered every 2-4 weeks. Due to the aging patient population, this creates burden on patients, their care takers as well as healthcare systems. The industry is moving towards the ultimate goal of developing drugs with longer…Read more

day: Pre-Conference Workshop